A nurse is assessing a client for potential complications related to obesity. Which condition is the client most at risk for due to obesity?

Choice A reason: Hard, formed stool is typical of descending or sigmoid colostomies, where the colon reabsorbs water. A transverse colostomy, located higher in the colon, has less water absorption, producing liquid stool. This statement is inaccurate, as transverse colostomy stool is not hard or formed.

Choice B reason: A transverse colostomy, located in the mid-colon, produces mostly liquid feces with mucus due to limited water reabsorption before the stoma. The proximal colon’s contents are less formed, and mucus from inflammation (common in IBD) is present, making this statement accurate for stool consistency.

Choice C reason: Soft, semi-formed stool is more typical of descending colostomies, where water absorption occurs longer. Transverse colostomies, higher in the colon, produce more liquid output due to shorter transit time. This statement is inaccurate, as it does not reflect transverse colostomy stool consistency.

Choice D reason: Dry, pellet-like stool is characteristic of constipation or distal colon output, not a transverse colostomy. The transverse colon’s contents are liquid due to minimal water reabsorption, especially in IBD with inflammation. This statement is inaccurate, as it misrepresents the expected stool consistency.

Choice A reason: Phenazopyridine is a urinary analgesic that relieves pain, burning, and irritation in the urinary tract by exerting a topical anesthetic effect on the uroepithelium. It is commonly used for symptomatic relief in UTIs, making this statement accurate, as it directly addresses its therapeutic role in managing urinary discomfort.

Choice B reason: Phenazopyridine is used short-term (typically 2 days) for symptom relief, not necessarily until an antibiotic course is completed. Antibiotics treat the underlying UTI, while phenazopyridine addresses symptoms. This statement is inaccurate, as their durations are independent, based on clinical need, not synchronized completion.

Choice C reason: Phenazopyridine is not contraindicated in UTIs; it is specifically indicated for symptomatic relief in these infections. It does not treat the infection but alleviates discomfort. This statement is inaccurate, as phenazopyridine is a standard adjunctive therapy in UTI management for pain relief.

Choice D reason: Phenazopyridine provides relief within hours, not almost immediately. Its onset requires absorption and distribution to the urinary tract, typically taking 1-2 hours. This statement is inaccurate, as the relief, while rapid, is not instantaneous, and patients should be informed of the expected timeframe.